AmerisourceBergen Corp (ABC.N)
BRIEF-AmerisourceBergen Corp Says CEO Steven Collis' FY 2017 Total Compensation Was $9.9 Mln Vs $10.0 Mln In FY 2016
* AMERISOURCEBERGEN CORP SAYS CEO STEVEN COLLIS' FY 2017 TOTAL COMPENSATION WAS $9.9 MILLION VERSUS $10.0 MILLION IN FY 2016 - SEC FILING Source text: (http://bit.ly/2mONZyU) Further company coverage:
* AMERISOURCEBERGEN ANNOUNCES OPERATING COMMITMENTS TO ADDRESS OPIOID DIVERSION AND ABUSE
(The following statement was released by the rating agency) NEW YORK, December 05 (Fitch) Fitch Ratings has assigned an 'A-' rating to AmerisourceBergen's (ABC) sale of $750 million senior notes due 2027 and $500 million senior notes due 2047. Proceeds are expected to be used to finance the acquisition of H.D. Smith for $815 million in cash and to redeem 4.875% senior notes due Nov. 15, 2019, and for general corporate purposes. See key terms of the notes below the list of rating actions. Fitch h
* AMERISOURCEBERGEN PRICES $750 MILLION 3.45% SENIOR NOTES DUE 2027 AND $500 MILLION 4.30% SENIOR NOTES DUE 2047 Source text for Eikon: Further company coverage:
A unit of AmerisourceBergen Corp, one of the largest U.S. drug wholesalers, has agreed to pay $625 million to resolve a U.S. government probe involving pre-filled syringes, the company said in a filing with U.S. securities regulators on Tuesday.
Nov 21 A unit of AmerisourceBergen Corp, one of the largest U.S. drug wholesalers, has agreed to pay $625 million to resolve a U.S. government probe into its pre-filled syringe program, the company said in a filing with U.S. securities regulators on Tuesday.
AmerisourceBergen Corp said on Monday it would buy privately held U.S. drug wholesaler H. D. Smith for $815 million in cash.
Nov 20 AmerisourceBergen Corp said on Monday it would buy privately held U.S. drug wholesaler H. D. Smith for $815 million in cash.
* AmerisourceBergen Corp - plans to fund acquisition through issuance of new long-term debt
AmerisourceBergen Corp said it expects stubbornly low generic drug prices, which have plagued drugmakers and wholesalers, to not deteriorate further next year, and brushed off concerns about Amazon's possible entry into the industry.